Matches in SemOpenAlex for { <https://semopenalex.org/work/W2600370003> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2600370003 abstract "3034 Background: CD105 (endoglin) is an endothelial cell membrane receptor highly expressed on angiogenic tumor vessels that is essential for angiogenesis and upregulated by hypoxia and VEGF inhibition. TRC105 is a human/mouse chimeric anti-CD105 monoclonal antibody that completed phase I testing and is being studied in multiple phase II trials. Methods: Pts with advanced solid tumors (non-CNS), ECOG PS 0-1, and normal organ function were treated with escalating doses of intravenously administered TRC105 plus bevacizumab (BEV) at 15 mg/kg q3wk or 10 mg/kg q2wk and assessed for safety, PK, and response. Results: Twelve pts were treated (3 with TRC105 at 3 mg/kg q1wk + BEV at 15 mg/kg q3wk, 5 with TRC105 at 6 mg/kg q1wk + BEV at 15 mg/kg q3wk, and 4 with TRC105 at 6 mg/kg q1wk + BEV at 10 mg/kg q2wk), and 10 have completed the DLT evaluation period. TRC105 at 6 mg/kg q1wk + BEV at 15 mg/kg q3wk resulted in grade 1-3 headaches with sinus congestion following the cycle 1 day 1 (C1D1) dose in 5 of 5 pts that improved with continued dosing. Treatment with BEV 10 mg/kg q2wk and sequential dosing with Bev starting on C1D1 and TRC105 on C1D8 resulted in decreased frequency and severity of headaches, allowing dose escalation to continue. TRC105 serum concentrations that saturate CD105 binding sites (>200 ng/mL) were achieved continuously at 6 mg/kg q1wk. At 3 mg/kg q1wk TRC105 + 15 mg/kg q3wk BEV, one pt with BEV-resistant ovarian cancer had stable disease for 6 cycles and one pt with refractory hepatocellular cancer who failed sorafenib and sunitinib had an AFP decrease from 1578 at baseline to 179 at the end of cycle 3. Two of three evaluable pts at 6 mg/kg q1wk TRC105 + 15 mg/kg q3wk BEV with VEGF-refractory tumors (HCC and CRC) are ongoing in C4 with stable disease. Dose escalation continues and TRC105 dose levels of 8 and 10 mg/kg are planned. Conclusions: The combination of TRC105 and BEV was tolerated with early evidence of activity in VEGF-refractory pts by sequential administration during initial dosing in C1." @default.
- W2600370003 created "2017-04-07" @default.
- W2600370003 creator A5005702417 @default.
- W2600370003 creator A5019995834 @default.
- W2600370003 creator A5036134937 @default.
- W2600370003 creator A5037497042 @default.
- W2600370003 creator A5059919595 @default.
- W2600370003 creator A5061366384 @default.
- W2600370003 creator A5069302126 @default.
- W2600370003 creator A5069690249 @default.
- W2600370003 creator A5075801763 @default.
- W2600370003 creator A5086993471 @default.
- W2600370003 creator A5087302389 @default.
- W2600370003 date "2012-05-20" @default.
- W2600370003 modified "2023-09-26" @default.
- W2600370003 title "A phase Ib dose-escalation study of TRC105 in combination with bevacizumab for advanced solid tumors." @default.
- W2600370003 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.3034" @default.
- W2600370003 hasPublicationYear "2012" @default.
- W2600370003 type Work @default.
- W2600370003 sameAs 2600370003 @default.
- W2600370003 citedByCount "0" @default.
- W2600370003 crossrefType "journal-article" @default.
- W2600370003 hasAuthorship W2600370003A5005702417 @default.
- W2600370003 hasAuthorship W2600370003A5019995834 @default.
- W2600370003 hasAuthorship W2600370003A5036134937 @default.
- W2600370003 hasAuthorship W2600370003A5037497042 @default.
- W2600370003 hasAuthorship W2600370003A5059919595 @default.
- W2600370003 hasAuthorship W2600370003A5061366384 @default.
- W2600370003 hasAuthorship W2600370003A5069302126 @default.
- W2600370003 hasAuthorship W2600370003A5069690249 @default.
- W2600370003 hasAuthorship W2600370003A5075801763 @default.
- W2600370003 hasAuthorship W2600370003A5086993471 @default.
- W2600370003 hasAuthorship W2600370003A5087302389 @default.
- W2600370003 hasConcept C121608353 @default.
- W2600370003 hasConcept C126322002 @default.
- W2600370003 hasConcept C143998085 @default.
- W2600370003 hasConcept C2776694085 @default.
- W2600370003 hasConcept C2777334693 @default.
- W2600370003 hasConcept C2777802072 @default.
- W2600370003 hasConcept C2993640289 @default.
- W2600370003 hasConcept C502942594 @default.
- W2600370003 hasConcept C71924100 @default.
- W2600370003 hasConceptScore W2600370003C121608353 @default.
- W2600370003 hasConceptScore W2600370003C126322002 @default.
- W2600370003 hasConceptScore W2600370003C143998085 @default.
- W2600370003 hasConceptScore W2600370003C2776694085 @default.
- W2600370003 hasConceptScore W2600370003C2777334693 @default.
- W2600370003 hasConceptScore W2600370003C2777802072 @default.
- W2600370003 hasConceptScore W2600370003C2993640289 @default.
- W2600370003 hasConceptScore W2600370003C502942594 @default.
- W2600370003 hasConceptScore W2600370003C71924100 @default.
- W2600370003 hasLocation W26003700031 @default.
- W2600370003 hasOpenAccess W2600370003 @default.
- W2600370003 hasPrimaryLocation W26003700031 @default.
- W2600370003 hasRelatedWork W1439434937 @default.
- W2600370003 hasRelatedWork W1521444791 @default.
- W2600370003 hasRelatedWork W2010835312 @default.
- W2600370003 hasRelatedWork W2021487267 @default.
- W2600370003 hasRelatedWork W2158728780 @default.
- W2600370003 hasRelatedWork W2165071603 @default.
- W2600370003 hasRelatedWork W2278662399 @default.
- W2600370003 hasRelatedWork W2284792721 @default.
- W2600370003 hasRelatedWork W2340483368 @default.
- W2600370003 hasRelatedWork W2440267340 @default.
- W2600370003 hasRelatedWork W2470159777 @default.
- W2600370003 hasRelatedWork W2562210181 @default.
- W2600370003 hasRelatedWork W2590683646 @default.
- W2600370003 hasRelatedWork W2599361077 @default.
- W2600370003 hasRelatedWork W2620380971 @default.
- W2600370003 hasRelatedWork W2889699526 @default.
- W2600370003 hasRelatedWork W2965547587 @default.
- W2600370003 hasRelatedWork W3031974260 @default.
- W2600370003 hasRelatedWork W3191891553 @default.
- W2600370003 hasRelatedWork W53689708 @default.
- W2600370003 isParatext "false" @default.
- W2600370003 isRetracted "false" @default.
- W2600370003 magId "2600370003" @default.
- W2600370003 workType "article" @default.